Clinical Trials
First ever study to apply therapeutic approach of global immune reconstitution to treatment of cancer patients
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard (Lyon), the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies...
Clinical Trials
FDA approves linagliptin tablets for the treatment of type 2 diabetes
Boehringer Ingelheim and Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes....
Clinical Trials
Gilead and MicroDose Therapeutx Announce License and Collaboration Agreement to Develop MDT-637
Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose's inhalable small molecule antiviral fusion inhibitor for the...
Clinical Trials
Biogen Idec Receives Positive Opinion from the CHMP and Authorisation from Health Canada on AVONEX PEN
Biogen Idec announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX(R) PEN(TM) for patients with relapsing multiple sclerosis (MS) and patients with a...
Clinical Trials
Boehringer Ingelheim’s lead hepatitis C compound moves into phase III – the first within the BI HCV portfolio
Boehringer Ingelheim announced the study outline for the pivotal Phase III clinical trials designed to evaluate BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus (HCV), the most...
Clinical Trials
Addex Initiates Phase IIa Clinical Trial of Dipraglurant-IR in Parkinson’s Disease Levodopa-Induced Dyskinesia (PD-LID)
Allosteric modulation company Addex Pharmaceuticals (SIX:ADXN) announced today the initiation of a Phase IIa clinical trial to evaluate dipraglurant in patients with Parkinson’s disease levodopa-induced dyskinesia (PD-LID), a debilitating movement disorder caused by long-term treatment with levodopa, the...
Clinical Trials
Adocia reports positive phase I clinical results on HinsBet(R), a fast-acting human insulin
Adocia, a privately-held biotechnology company specialized in regenerative medicine and in the treatment of chronic diseases, announced today positive results from its phase I clinical study evaluating the safety and clinical utility of HinsBet(R), its fast-acting human insulin product...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read